Ardizzoni A, Cafferata MA, Paganuzzi M, Filiberti R, Marroni P, Neri M, Fontana V, Nicolo G, Perdelli L, Stampino CG, Rosso R, Puntoni R (2001) Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma. Cancer 92: 1896-1904
Bernstein JJ, Goldberg WJ, Laws Jr ER (1994) Migration of fresh human malignant astrocytoma cells into hydrated gel wafers in vitro. J Neurooncol 18(2): 151-161
Brabender J, Danenberg KD, Metzger R, Schneider PM, Park J, Salonga D, Holscher AH, Danenberg PV (2001) Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 7: 1850-1855
Cantero R, Torres AJ, Maestro M, Fernandez C, Hernando F, Del Barco V, Sanz T, Balibrea JL (1999) Use of possible synergistic expression of p53 and p185 as a prognostic tool for stage I non-small-cell lung cancer. World J Surg 23: 1294-1299
Cantero R, Torres AJ, Maestro ML, Hernando F, Sanz MT, Del BV, , Gomez A, Fernandez C, Balibrea JL (2000) Prognostic value of the quantified expression of p185 in non-small cell lung cancer. J Thorac Cardiovasc Surg 119: 1119-1125
Carbognani P, Tincani G, Crafa P, Sansebastiano G, Pazzini L, Zoni R, Bobbio A, Rusca M (2002) Biological markers in non-small cell lung cancer. Retrospective study of 10 years follow-up after surgery. J Cardiovasc Surg 43: 545-548
D'Amico TA, Massey M, Herndon JE, Moore MB, Harpole Jr DH (1999) A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 117: 736-743
Diez M, Pollan M, Maestro M, Torres A, Ortega D, Gomez A, Sanchez A, Hernando F, Balibrea JL (1997) Prediction of recurrence by quantification of p185 neu protein in non-small-cell lung cancer tissue. Br J Cancer 75(5): 684-689
Fu XL, Zhu XZ, Shi DR, Xiu LZ, Wang LJ, Zhao S, Qian H, Lu HF, Xiang YB, Jiang GL (1999) Study of prognostic predictors for non-small cell lung cancer. Lung Cancer 23: 143-152
Giatromanolaki A, Gorgoulis V, Chetty R, Koukourakis MI, Whitehouse R, Kittas C, Veslemes M, Gatter KC, Iordanoglou I (1996a) C-erbB-2 oncoprotein expression in operable non-small cell lung cancer. Anticancer Res 16: 987-993
Giatromanolaki A, Koukourakis MI, O'Byrne K, Kaklamanis L, Dicoglou C, Trichia E, Whitehouse R, Harris AL, Gatter KC (1996b) Non-small cell lung cancer: c-erbB-2 overexpression correlates with low angiogenesis and poor prognosis. Anticancer Res 16: 3819-3825
Graziano SL, Kern JA, Herndon JE, Tatum A, Brisson ML, Memoli V, Sugarbaker D, Skarin AT, Kreisman H, Green MR (1998) Analysis of neuroendocrine markers. HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer 21: 203-211
Greatens TM, Niehans GA, Rubins JB, Jessurun J, Kratzke RA, Maddaus MA, Niewoehner DE (1998) Do molecular markers predict survival in non-small-cell lung cancer? Am J Respir Crit Care Med 157: 1093-1097
Ran H, Landreneau RJ, Santucci TS, Tung MY, Macherey RS, Shackney SE, Sturgis CD, Raab SS, Silverman JF (2002) Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer. Hum Pathol 33: 105-110
Harpole Jr DH, Herndon JE, Wolfe WG, Iglehart JD, Marks JR (1995a) A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 55: 51-56
Harpole Jr DH, Marks JR, Richards WG, Herndon JE, Sugarbaker DJ (1995b) Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients. Clin Cancer Res 1: 659-664
Harpole Jr DH, Richards WG, Herndon JE, Sugarbaker DJ (1996) Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann Thorac Surg 61: 1470-1476
Hirsch FR, Varella-Garcia M, Franklin WA, Veve R, Chen L, Helfrich B, Zeng C, Baron A, Bunn Jr PA (2002) Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer 86: 1449-1456
Hsieh CC, Chow KC, Fahn HJ, Tsai CM, Li WY, Huang MH, Wang LS (1998) Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung. Ann Thorac Surg 66: 1159-1163
Hung MC, Lau YK (1999) Basic science of HER-2/neu: a review. Semin Oncol 26: 51-59
Kanters SD, Lammers JW, Voest EE (1995) Molecular and biological factors in the prognosis of non-small cell lung cancer. Eur Respir J 8: 1389-1397
Kern JA, Schwartz DA, Nordberg JE, Weiner DB, Greene MI, Torney L, Robinson RA (1990) p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 50: 5184-5187
Kern JA, Slebos RJ, Top B, Rodenhuis S, Lager D, Robinson RA, Weiner D, Schwartz DA (1994) C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 93: 516-520
Kim YC, Park KO, Kern JA, Park CS, Lim SC, Jang AS, Yang JB (1998) The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients. Lung Cancer 22: 181-190
Koukourakis MI, Giatromanolaki A, Guddo F, Kaklamanis L, Vignola M, Kakolyris S, Turley H, Georgoulias V, Bonsignore G, Gatter KC, Harris AL (2000) c-erbB-2 and episialin challenge host immune response by HLA class I expression in human non-small-cell lung cancer. J Immunother 23: 104-114
Koukourakis MI, Giatromanolaki A, O'Byrne KJ, Whitehouse RM, Talbot DC, Gatter KC, Harris AL (1997) Potential role of bcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer. Int J Cancer 74: 565-570
Kwiatkowski DJ, Harpole Jr DH, Godleski J, Herndon JE, Shieh DB, Richards W, Blanco R, Xu HJ, Strauss GM, Sugarbaker DJ (1998) Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. J Clin Oncol 16: 2468-2477
Lee JS, Yoon A, Kalapurakal SK, Ro JY, Lee JJ, Tu N, Hittelman WN, Hong WK (1995) Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J Clin Oncol 13: 1893-1903
Liao M, Wang H, Lin Z, Feng J, Zhu D (2001) Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer. Lung Cancer 33: 125-132
MacKinnon M, Kerr KM, King G, Kennedy MM, Cockburn JS, Jeffrey RR (1997) p53, c-erbB-2 and nm23 expression have no prognostic significance in primary pulmonary adenocarcinoma. Eur J Cardiothorac Surg 11: 838-842
Marks JR, Humphrey PA, Wu K, Berry D, Bandorenko N, Kerns BJ, Iglehart JD (1994) Overexpression of p53 and HER-2/neu protein as prognostic markers in early breast cancer. Ann Surg 219(4): 332-341
Meert AP, Martin B, Delmotte P, Berghmans T, Lafitte JJ, Mascaux C, Paesmans M, Steels E, Verdebout JM, Sculier JP (2002a) The role of EGF-R expression on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Eur Resp J 20: 975-981
Meert AP, Paesmans M, Martin B, Delmotte P, Berghmans T, Verdebout JM, Lafitte JJ, Mascaux C, Sculier JP (2002b) The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 87: 694-701
Moldvay J, Scheid P, Wild P, Nabil K, Siat J, Borrelly J, Marie B, Farre G, Labib T, Pottier G, Sesboue R, Bronner C, Vignaud JM, Martinet Y, Martinet N (2000) Predictive survival markers in patients with surgically resected non-small cell lung carcinoma. Clin Cancer Res 6: 1125-1134
Mulrow CD (1987) The medical review article: state of the science. Ann Intern Med 106: 485-488
Nemunaitis J, Klemow S, Tong A, Courtney A, Johnston W, Mack M, Taylor W, Solano M, Stone M, Mallams J, Mues G (1998) Prognostic value of K-ras mutations, ras oncoprotein, and c-erb B-2 oncoprotein expression in adenocarcinoma of the lung. Am J Clin Oncol 21: 155-160
Ochiai A, Akimoto S, Kanai Y, Shibata T, Oyama T, Hirohashi S (1994) c-erbB-2 gene product associates with catenins in human cancer cells. Biochem Biophys Res Commun 205(1): 73-78
Osaki T, Mitsudomi T, Oyama T, Nakanishi R, Yasumoto K (1995) Serum level and tissue expression of c-erbB-2 protein in lung adenocarcinoma. Chest 108(1): 157-162
Paesmans M, Sculier JP (1998) Facteurs pronostiques des cancers bronchopulmonaires. Arnette 239-247
Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834
Pastorino U, Andreola S, Tagliabue E, Pezzella F, Incarbone M, Sozzi G, Buyse M, Menard S, Pierotti M, Rilke F (1997) Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 15: 2858-2865
Pfeiffer P, Clausen PP, Andersen K, Rose C (1996) Lack of prognostic signifiance of epidermal growth factor receptor and the oncoprotein p185 HER-2 in patients with systemically untread non-small-cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer 74: 86-91
Potti A, Willardson J, Forseen C, Kishor GA, Koch M, Hebert B, Levitt R, Mehdi SA (2002) Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma. Lung Cancer 36: 257-261
Press MF, Hung G, Godolphin W, Slebos RJ, Slamon DJ (1994) Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54(10): 2771-2777
Pupa SM, Menard S, Morelli D, Pozzi B, De Palo G, Colnaghi MI (1993) The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 8(11): 2917-2923
Schlechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, Weinberg RA (1984) The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312: 513-516
Schneider PM, Praeuer HW, Stoeltzing O, Boehm J, Manning J, Metzger R, Fink U, Wegerer S, Hoelscher AH, Roth JA (2000) Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer. Br J Cancer 83: 473-479
Selvaggi G, Scagliotti GV, Torri V, Novello S, Leonardo E, Cappia S, Mossetti C, Ardissone F, Lausi P, Borasio P (2002) Her-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma. Impact on long-term survival. Cancer 94(10): 2669-2674
Shou Y, Hirano T, Gong Y, Kato Y, Yoshida K, Ohira T, Ikeda N, Konaka C, Ebihara Y, Zhao F, Kato H (2001) Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer. Br J Cancer 85: 1706-1712
Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, Meert AP, Vallot F, Lafitte JJ, Sculier JP (2001) Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18: 705-719
Tateishi M, Ishida T, Kohdono S, Hamatake M, Fukuyama Y, Sugimachi K (1994) Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma. Surg Oncol 3: 109-113
Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K (1991) Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 27: 1372-1375
Tsai CM, Chang KT, Wu LH, Chen JY, Gazdar AF, Mitsudomi T, Chen MH, Perng RP (1996) Correlation between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res 56(1): 206-209
Visscher DW, Yadrandji S, Tabaczka P, Kraut M, Sarkar FH (1997) Clinicopathologic analysis of k-ras, p53, and ERBB-2 gene alterations in pulmonary adenocarcinoma. Diagn Mol Pathol 6: 64-69
Volm M, Drings P, Mattern J, Wodrich W (1993a) Prognostic value of oncoproteins for the survival of patients with non-small cell lung carcinomas. Int J Oncol 2: 767-772
Volm M, Drings P, Wodrich W (1993b) Prognostic significance of the expression of c-fos, c-jun and c-erbB-1 ooncogene products in human squamous cell lung carcinomas. J Cancer Res Clin Oncol 119: 507-510
Volm M, Efferth T, Mattern J (1992) Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations. Anticancer Res 12: 11-20
Yu CJ, Shun CT, Yang PC, Lee YC, Shew JY, Kuo SH, Luh KT (1997) Sialomucin expression is associated with erbB-2 oncoprotein overexpression, early recurrence, and cancer death in non-small-cell lung cancer. Am J Respir Crit Care Med 155: 1419-1427
Yusuf S, Peto R, Lewis J, Collins R, Sleight P (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27: 335-371
